AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT00079105
Drug: cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Treatment
Trial: NCT00079105
Drug: prednisolone
RxNorm normalized name: Prednisolone
DrugBank: Prednisolone acetate (DB15566)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Treatment
Trial: NCT00733824
Drug: AMD3100
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01166984
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single intravenous infusion of normal saline (0.9% sodium chloride) administered over approximately 10 minutes
Trial: NCT01840592
Drug: Doxorubicin
RxNorm normalized name: Doxorubicin
DrugBank: Doxorubicin (DB00997)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT01351129
Drug: Formulation 2
RxNorm normalized name: Hep B, unspecified formulation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 150-mg modified release capsule, short duration (single dose)
Trial: NCT01351129
Drug: Formulation 3
RxNorm normalized name: Hep B, unspecified formulation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 150-mg modified release capsule, long duration (single dose)
Trial: NCT03246009
Drug: rHSA/GCSF
FDA approved: no
EMA approved: no
PMDA approved: no
Description: single injection-1.8mg
Trial: NCT03246009
Drug: rHSA/GCSF
FDA approved: no
EMA approved: no
PMDA approved: no
Description: single injection-2.1mg
Trial: NCT03246009
Drug: rHSA/GCSF
FDA approved: no
EMA approved: no
PMDA approved: no
Description: single injection-2.4mg
Trial: NCT03246009
Drug: rHSA/GCSF
FDA approved: no
EMA approved: no
PMDA approved: no
Description: multiple injection-1.8mg
Trial: NCT03246009
Drug: rHSA/GCSF
FDA approved: no
EMA approved: no
PMDA approved: no
Description: multiple injection-2.1mg
Trial: NCT03246009
Drug: rHSA/GCSF
FDA approved: no
EMA approved: no
PMDA approved: no
Description: multiple injection-2.4mg
Trial: NCT01785602
Drug: QAW039
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Capsules
Trial: NCT01785602
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Capsules
Trial: NCT03380039
Drug: Cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Cyclophosphamide is used for lymphodepletion.
Trial: NCT03212586
Drug: BAY1902607
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Escalating doses of BAY1902607; single dose administration; different dosage forms (redosing of BAY1902607 at dose group 4 with different formulations; redosing of BAY1902607 solid formulation at dose group 4 together with food)
Trial: NCT03212586
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Escalating doses of Placebo; single dose administration; different dosage forms (redosing of Placebo at dose group 4 with different formulations; redosing of Placebo solid formulation at dose group 4 together with food)
Trial: NCT02360618
Drug: Simvastatin
RxNorm normalized name: Simvastatin
DrugBank: Simvastatin (DB00641)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: See Group Description
Trial: NCT01511887
Drug: Oral Ibuprofen
RxNorm normalized name: ibuprofen Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10mg/kg oral ibuprofen followed by two 5mg/kg in 12 hours intervals. If there was no improvement after first cycle of treatment this treatment was repeated.
Trial: NCT00876317
Drug: Etoricoxib 60 mg
RxNorm normalized name: etoricoxib 60 MG
DrugBank: Etoricoxib (DB01628)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Etoricoxib 60 mg per oz per day for 14 days
Trial: NCT00876317
Drug: Etoricoxib 90 mg
RxNorm normalized name: etoricoxib 90 MG
DrugBank: Etoricoxib (DB01628)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Etoricoxib 90 mg per oz for 14 days
Trial: NCT01544972
Drug: Oral paracetamol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients will receive oral paracetamol 15 mg/kg per dose every 6 hours.
Trial: NCT01544972
Drug: Oral ibuprofen
RxNorm normalized name: ibuprofen Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients will receive oral ibuprofen at an initial dose of 10 mg/kg, followed by 5 mg/kg at 24 and 48 h.
Trial: NCT00003380
Drug: pegylated liposomal doxorubicin hydrochloride
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00656253
Drug: Herbal Medicinal Mixture (Roucongrong, Heshouwu etc.)
RxNorm normalized name: brown mixture
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 12 months period of Herbal Medicinal Mixture per day plus 1 month wash-out period without herbal medicine
Trial: NCT00656253
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 12 months period of placebo plus 1 month period without placebo
Trial: NCT00448058
Drug: GSK372475
FDA approved: no
EMA approved: no
PMDA approved: no
Description: daily administration during the 10-week treatment phase
Trial: NCT00448058
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: daily administration during the 10-week treatment phase
Trial: NCT02598349
Drug: Capecitabine
RxNorm normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Concomitant oral chemotherapy, capecitabine 1000mg by mouth twice daily, 5 days a week (M-F) on radiation days only.
Trial: NCT00841126
Drug: Magnesium iron hydroxycarbonate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 500 mg tablets, administered orally: initial dosage 500 or 1000 mg (total daily dose 1500 or 3000 mg) depending on serum phosphate concentration, titrated to a maximum DAILY dose of 9000 mg). The total daily dose should be divided and taken with meals. Any SINGLE dose should not exceed 3000 mg.
Trial: NCT00841126
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0 mg (500 mg-size) tablets, administered orally: The total daily dose should be divided and taken with meals. Any SINGLE dose should not exceed 6 tablets.
Trial: NCT00653224
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0 mg daily (matching oral tablet) for 14 days
Trial: NCT04771741
Drug: Meloxicam
RxNorm normalized name: Meloxicam
DrugBank: Meloxicam (DB00814)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 15 mg once daily, beginning post-op day 4
Trial: NCT01360034
Drug: Indomethacin
RxNorm normalized name: Indomethacin
DrugBank: Indomethacin (DB00328)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Indomethacin: 50 mg vo as a single dose upon admission and then 25 mg vo every 6 hours for 48 hours.
Trial: NCT02573324
Drug: Placebo for ABT-414
RxNorm normalized name: ABT-925
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IV Infusion (IV)
Trial: NCT01455883
Drug: ITCA 650 60 mcg/day
FDA approved: no
EMA approved: no
PMDA approved: no
Description: exenatide in DUROS
Trial: NCT00785226
Drug: RDEA119
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Total daily doses of RDEA119 from 10 mg/day to 100 mg/day
Trial: NCT02564471
Drug: Doxycycline
RxNorm normalized name: Doxycycline
DrugBank: Doxycycline (DB00254)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: FDA approve dosing schedule
Trial: NCT01595516
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gelatin capsule to be taken by mouth once per day for 12 weeks
Trial: NCT01677195
Drug: ACCS100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ACCS100 is not absorbed. The dose is estimated based on the volume of the gastrointestinal tract. We estimate that the average human intestinal tract has a volume of approximately 4 liters. In the high dose group, the effective concentration in the gut is 0.75 milligrams per milliliter. In the low dose, the effective concentration in the gut is 0.375 milligrams per milliliter. The test article is made by filling gelatin capsules with 500 milligrams of ACCS100. There are no excipients used in the manufacturing process of the test article.
Trial: NCT01677195
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo is calcium carbonate, USP. This calcium mineral does not absorb mycotoxins, specifically aflatoxin and fumonisin. This mineral has approximately the same physical appearance as active test article.
Trial: NCT01312909
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral placebo for twelve weeks,follow-up through Week 52
Trial: NCT03540901
Drug: Placebo oral capsule
RxNorm normalized name: Placebo Oral Capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administration of equally looking placebo capsules in the morning and evening, starting 24 hours before departure to 3100m
Trial: NCT00659646
Drug: gentamicin-collagen sponge and levofloxacin
RxNorm normalized name: Levofloxacin
DrugBank: Levofloxacin (DB01137)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Topical Gentamicin Collagen Sponge: 10 × 10 cm in size And 750 mg tablet po every 24 hours or 750 mg IV administered by slow infusion over 90 minutes every 24 hours.
Trial: NCT00509197
Drug: Placebo (sham inhaler)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01513772
Drug: Normal saline 0.9%
RxNorm normalized name: BD Posiflush Normal Saline 0.9% Prefilled Syringe Solution for Injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Normal saline(guess as 4㎍/mL) : 0.4㎍/kg/hr infusion until extubation
Trial: NCT02086591
Drug: Doxycycline
RxNorm normalized name: Doxycycline
DrugBank: Doxycycline (DB00254)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT01774903
Drug: TTS-fentanyl
RxNorm normalized name: Fentanyl
DrugBank: Fentanyl (DB00813)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: TTS-fentanyl patches releasing drug at the rate of 12.5 microgram (µg) per hour for 3 days. The patches will be replaced every 3 days until 30 days.
Trial: NCT02309385
Drug: Prednisolone Acetate (1%) Eye Drops
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01400594
Drug: HTU-520 Patch
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Terbinafine hydrochloride patch
Trial: NCT03285646
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subcutaneous (SC) every 4 weeks (Q4W)
Trial: NCT03599427
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo is administrated at induction of anesthesia and at the end of surgery (0.075 ml/kg)
Trial: NCT02984397
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02870218
Drug: Smoking research cigarettes with e-cigarette
RxNorm normalized name: E-Z Scrub with Ultradex
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Smoking research cigarettes with varying levels of nicotine with unlimited access to 15 mg/ml nicotine-containing e-cigarettes.
Trial: NCT01421810
Drug: rhCG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 25 mcg IV
Trial: NCT00801684
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Supplied as an empty size-2 capsule and administered as a single dose via C2S inhaler.
Trial: NCT00801684
Drug: TrIP-2D
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Trospium inhalation powder containing 100 mcg TrCl (trospium chloride), supplied as dry powder in size-2 capsules and administered as a single dose via C2S inhaler.
Trial: NCT00801684
Drug: TrIP-2SS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Trospium inhalation powder containing 100 mcg TrCl (trospium chloride), supplied as dry powder in size-2 capsules and administered as a single dose via C2S inhaler.
Trial: NCT00801684
Drug: TrIP-2D
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Trospium inhalation powder containing 400 mcg TrCl (trospium chloride), supplied as dry powder in size-2 capsules and administered as a single dose via C2S inhaler.
Trial: NCT02691858
Drug: Hydrocortisone
RxNorm normalized name: Hydrocortisone
DrugBank: Hydrocortisone succinate (DB14545)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: 10 mg/kg with Resuscitation before attempting pneumatic reduction, single dose with Resuscitation before attempting reduction
Trial: NCT00343187
Drug: ACZONE (dapsone) Gel, 5%
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00035906
Drug: DEX PS DDS®
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02113020
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral admininstration of Placebo
Trial: NCT00767624
Drug: Antidepressant
RxNorm normalized name: Antidepressant
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Possible antidepressants are sertraline, escitalopram, desvenlafaxine, based on past history, response and tolerance
Trial: NCT03050086
Drug: BPX-04 1% minocycline topical gel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: once daily administration of topical minocycline gel to face
Trial: NCT03050086
Drug: BPX-04 2% minocycline topical gel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: once daily administration of topical minocycline gel to face
Trial: NCT03050086
Drug: BPX-04 vehicle topical gel
RxNorm normalized name: Neisseria meningitidis group B strain NZ98/254 outer membrane vesicle
FDA approved: no
EMA approved: no
PMDA approved: no
Description: once daily administration of topical minocycline gel to face
Trial: NCT00491686
Drug: AZD6765
FDA approved: no
EMA approved: no
PMDA approved: no
Description: intravenous infusion
Trial: NCT01595620
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control: small amount of alcohol with no THC, administered over 10 minutes
Trial: NCT00778830
Drug: FOLFIRI
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Irinotecan will be administered intravenously at a dose of 180 mg/m\^2 along with folinic acid administration intravenously at a dose of 400 mg/m\^2 (racemic) or 200 mg/m\^2 (L-form) and 5-fluorouracil will be administered intravenously at a dose of 400 mg/m\^2 bolus followed by a 46-hour continuous infusion of 2,400 mg/m\^2 given biweekly until disease progression, death, or consent withdrawal.
Trial: NCT00131287
Drug: Extract of Agaricus blazei Murill
RxNorm normalized name: Agaricus blazei whole extract
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02029924
Drug: Humalog®
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single dose of 0.2 /Kg body weight injected subcutaneously (under the skin)
Trial: NCT00420680
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo given at reappearance of T2 after 0.6 mg/kg rocuronium
Trial: NCT03063827
Drug: OnabotulinumtoxinA 200 UNT
RxNorm normalized name: onabotulinumtoxinA 200 UNT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patient in the treatment arm received a single injection of onabotulinumtoxinA 200 UNT to the detrusor muscle at 20 sites of the bladder body.
Trial: NCT00778830
Drug: FOLFOX
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oxaliplatin will be administered intravenously at a dose of 100 mg/m\^2 along with folinic acid administration intravenously at a dose of 400 mg/m\^2 (racemic) or 200 mg/m\^2 (L-form) and 5-fluorouracil administration intravenously at a dose of 400 mg/m\^2 bolus followed by a 46-hour continuous infusion of 2,400 mg/m\^2 given biweekly until disease progression, death, or consent withdrawal.
Trial: NCT03843359
Drug: GSK3745417
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GSK3745417 will be administered.
Trial: NCT01767116
Drug: ABT-450/r/ABT-267, ABT-333
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tablet; ABT-450 coformulated with ritonavir and ABT-267, ABT-333 tablet
Trial: NCT02209324
Drug: ASP2151
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT03083288
Drug: [18F]FluorThanatrace
FDA approved: no
EMA approved: no
PMDA approved: no
Description: \[18F\]FluorThanatrace is a radiotracer for PET/CT
Trial: NCT01455675
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo, 70 ml gargling solution, once daily
Trial: NCT00312507
Drug: Bovine Lipid Extract Surfactant (administered by lavage)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00312507
Drug: Bovine Lipid Extract Surfactant (administered by bolus)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT03541980
Drug: Acetaminophen
RxNorm normalized name: Acetaminophen
DrugBank: Acetaminophen (DB00316)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administration of 15 mg/kg (1000 mg max dose) of IV acetaminophen
Trial: NCT03541980
Drug: Normal saline
RxNorm normalized name: Normal Saline Flush
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Normal saline volume equivalent
Trial: NCT01728467
Drug: RVX000222
FDA approved: no
EMA approved: no
PMDA approved: no
Description: capsule, 200 mg, administer with food, 100 mg twice daily 10-12 hrs apart, 31-35 days
Trial: NCT01728467
Drug: Placebo, RVX000222
FDA approved: no
EMA approved: no
PMDA approved: no
Description: capsule, administer with food, twice daily 10-12 hrs apart, 31-35 days
Trial: NCT03783559
Drug: chemotherapy±target therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: chemotherapy±target therapy
Trial: NCT01391117
Drug: placebo.
FDA approved: no
EMA approved: no
PMDA approved: no
Description: panel 1: 2 participants receive placebo at a q24h regimen.
Trial: NCT01391117
Drug: placebo.
FDA approved: no
EMA approved: no
PMDA approved: no
Description: panel 3: 2 participants receive placebo. Actual dose and dose regimen (q12h or q24h) to be selected based on the results of the panels 1 and 2.
Trial: NCT01391117
Drug: TMC649128.
FDA approved: no
EMA approved: no
PMDA approved: no
Description: panel 2, arm 1: 8 participants receive a q12h regimen of TMC649128 at a selected dose based on results of panel 1.
Trial: NCT01391117
Drug: placebo.
FDA approved: no
EMA approved: no
PMDA approved: no
Description: panel 2, arm 2: 2 participants receive placebo at a q24h regimen.
Trial: NCT01391117
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: panel 4, arm 1: 10 participants receive PegIFN a-2a/RBV in combination with placebo, administered q12h or q24h, for 14 days. Actual dose and dose regimen (12h or 24h) is to be selected based on panels 1, 2 and 3.
Trial: NCT01391117
Drug: TMC649128
FDA approved: no
EMA approved: no
PMDA approved: no
Description: panel 4, arm 2: 10 participants receive PegIFN a-2a/RBV in combination with TMC649128, administered q12h or q24h, for 14 days. Actual dose and dose regimen (12h or 24h) is to be selected based on panels 1, 2 and 3.
Trial: NCT01391117
Drug: TMC649128.
FDA approved: no
EMA approved: no
PMDA approved: no
Description: panel 2, arm 2: 8 participants receive a q24h regimen TMC649128 at a dose based on results of panel 1.
Trial: NCT01391117
Drug: TMC649128
FDA approved: no
EMA approved: no
PMDA approved: no
Description: panel 3: 8 participants receive TMC649128. Actual dose and dose regimen (q12h or q24h) to be selected based on the results of the panels 1 and 2.
Trial: NCT01391117
Drug: TMC649128.
FDA approved: no
EMA approved: no
PMDA approved: no
Description: panel 1: 8 participants receive a q24h regimen at 1000 mg of TMC649128.
Trial: NCT01391117
Drug: placebo.
FDA approved: no
EMA approved: no
PMDA approved: no
Description: panel 2, arm 1: 2 participants receive placebo at a q12h regimen.
Trial: NCT02041455
Drug: Melatonin and Placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02041455
Drug: Melatonin and Amitriptylin
RxNorm normalized name: amitriptyline and psycholeptics
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT03384667
Drug: Maekmoondong-tang
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: MMDT is a Herbal medicine consist of six herbs.
Trial: NCT03384667
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The granules do not contain any active ingredients.
Trial: NCT01259193
Drug: Sorafenib and Zoledronic Acid
RxNorm normalized name: Zoledronic Acid
DrugBank: Zoledronic acid (DB00399)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Sorafenib ,tablet,400mg Bid ,until patient can not tolerance Zoledronic Acid ,powder for injection,4mg per 3 week for 1 year
Trial: NCT02203591
Drug: 3M CHG/IPA Prep C
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Apply topically for 30 seconds to the abdominal region or 2 minutes to the inguinal region, and allow to dry for 3 minutes.
Trial: NCT02203591
Drug: 3M CHG/IPA Prep CH
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Apply topically for 30 seconds to the abdominal region or 2 minutes to the inguinal region, and allow to dry for 3 minutes.
Trial: NCT02203591
Drug: Normal Saline
RxNorm normalized name: Normal Saline Flush
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Apply topically for 30 seconds to the abdominal region or 2 minutes to the inguinal region, and allow to dry for 3 minutes.
Trial: NCT04629664
Drug: FX-322
RxNorm normalized name: Prevail-FX
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Active Comparator
Trial: NCT03383588
Drug: Fentanyl
RxNorm normalized name: Fentanyl
DrugBank: Fentanyl (DB00813)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: intrathecal fentanyl 10 mcg. Fentanyl (also spelled fentanil) is an opioid which is used as a pain medication and together with other medications for anesthesia.
Trial: NCT03383588
Drug: Epinephrine
RxNorm normalized name: Epinephrine
DrugBank: Epinephrine (DB00668)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Epinephrine injection is used along with emergency medical treatment to treat life-threatening allergic reactions caused by insect bites or stings, foods, medications, latex, and other causes. Epinephrine is in a class of medications called alpha- and beta-adrenergic agonists (sympathomimetic agents). It works by relaxing the muscles in the airways and tightening the blood vessels.
Trial: NCT05801627
Drug: SAL067
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SAL067 6mg(2 tablet) and Metformin ≥1500mg
Trial: NCT05801627
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (2 tablet) and Metformin ≥1500mg
Trial: NCT00580905
Drug: Adenosine
RxNorm normalized name: Adenosine
DrugBank: Adenosine phosphate (DB00131)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: IV infusion of adenosine at a dose of 80 mcg/kg/min for 30 minutes.